查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800780

2025 年至 2033 年伴随诊断市场报告（按产品与服务、技术（免疫组织化学、聚合酶炼式反应、原位杂交、即时 PCR、基因定序等）、适应症、最终用户和地区划分）

Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球伴随诊断市场规模达76亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到223亿美元，2025-2033年期间的复合年增长率（CAGR）为12.11%。北美凭藉其先进的医疗基础设施、个人化医疗的普及率以及强有力的监管支持，引领市场发展。该地区还受益于对研究运营的大量投资以及越来越多的生物技术和製药公司。癌症发生率的上升、对个人化医疗的需求的不断增长以及包括新一代定序（NGS）在内的持续技术进步，是推动市场成长的一些主要因素。

个人化医疗是指根据个人基因图谱客製化治疗方案，这是推动伴随诊断市场需求成长的关键因素。根据患者独特的基因图谱匹配特定治疗方案需要精准的诊断工具，因此对伴随诊断的需求日益增长，因为这种诊断工具有助于指导治疗选择，从而改善疗效并减少副作用。此外，诊断技术的进步，尤其是分子诊断和新一代定序 (NGS) 的进步，显着提高了伴随诊断的精确度和可靠性。这些进步使得基因突变和生物标记的检测更加精准，从而提高了治疗的有效性，并推动了医疗环境中对伴随诊断的需求。此外，医疗保健领域的投资也越来越侧重于精准医疗，即利用诊断测试来客製化治疗方案。随着越来越多的医疗保健系统采用标靶治疗和个人化治疗方案，对伴随诊断的需求也随之增加，尤其是在肿瘤领域，因为客製化治疗方案至关重要。

全球伴随诊断市场趋势：

基因治疗和罕见疾病诊断的进展

随着基因疗法在遗​​传性疾病中的应用日益广泛，对确保这些疗法安全有效的诊断工具的需求也日益增长。伴随诊断在确定哪些患者符合基因治疗条件方面发挥着至关重要的作用，尤其是在罕见遗传性疾病中，其治疗效果很大程度上依赖于特定的生物标记。这些诊断有助于识别可能影响治疗效果的现有抗体或遗传因子，确保患者获得最合适的治疗。诊断和製药行业的主要参与者正在积极发挥这一关键作用，他们正在开发并获得监管部门批准的先进伴随诊断检测方法，以促进基因疗法的安全有效应用。 2024年，Labcorp公司获得FDA批准其nAbCyte™抗AAVRh74var HB-FE检测试剂盒，这是辉瑞公司用于治疗乙型血友病的基因疗法BEQVEZ™（fidanacogene elaparvovec-dzkt）的伴随诊断试剂盒。此检测试剂盒可辨识患者体内预先存在的抗AAVRh74var抗体，确保基因治疗的安全有效。此次批准标誌着罕见遗传疾病基因治疗诊断领域的突破。

人工智慧在诊断上的应用

人工智慧工具透过检查大量数据集（例如基因和临床资料）来提高诊断测试的速度、准确性和效率，从而以无与伦比的精度找出生物标记。人工智慧演算法可以帮助预测患者对特定疗法的反应，从而製定更有针对性的治疗策略。在肿瘤学和各种复杂情况下，人工智慧改善了临床试验患者的筛选流程，确保只纳入最有可能从治疗中受益的患者。公司之间的策略合作进一步巩固了这项技术进步，它们整合了人工智慧解决方案来改善诊断流程并加速临床试验的进展。 2024 年，ABION 和 Deep Bio 在韩国首尔签署了一份谅解备忘录，合作进行人工智慧驱动的伴随诊断和癌症临床试验。此次合作将 Deep Bio 的人工智慧病理学工具整合到 ABION 的药物管线中，以提高患者选择的精确度并加快试验效率。这为 ABION 正在进行的肺癌治疗联合试验提供了支持。

增加医疗保健投资

由于全球医疗体系致力于提高治疗效果并降低成本，医疗保健投资是影响市场的关键因素。政府、私人投资者和医疗机构正致力于个人化和精准医疗，这直接关係到伴随诊断的应用。透过精准定位最有效的疗法，伴随诊断可以最大限度地减少传统治疗中常见的反覆试验，从而更有效率地配置医疗资源。此外，人们日益重视基于价值的医疗保健，即将报销与患者结果而非医疗量挂钩，这与伴随诊断在提高治疗精准度方面的作用高度契合。伴随诊断促进的标靶治疗的成本效益进一步巩固了其在全球医疗体系中的地位。随着医疗体系面临的经济压力不断增加，对诸如伴随诊断等能够提升医疗效率和疗效的工具的投资正在推动市场成长。

全球伴随诊断市场的成长动力：

人口老化加剧

随着老年人口的增长，癌症、心臟病和神经系统疾病等慢性疾病和与年龄相关的疾病的盛行率也在上升。老年人通常需要更个人化的治疗方案，根据其基因特征进行客製化治疗才能获得最佳疗效。世界卫生组织 (WHO) 指出，到 2030 年，全球每六个人中就有一人年龄在 60 岁或以上，预计到 2050 年这一数字将攀升至 21 亿人。这种人口结构变化需要增加和增强诊断服务，从而推动对卓越诊断仪器和检测解决方案的需求。伴随诊断使医疗保健专业人员能够根据特定的基因特征量身定制治疗方案，从而提高治疗效果并降低不良反应的可能性。这种个人化医疗保健趋势对于满足老龄化人口的复杂需求至关重要。

策略伙伴关係与合作

诊断公司与製药公司之间的合作与伙伴关係促进了诊断工具与创新疗法的结合，确保合适的患者获得最有效的治疗。透过整合药物开发和诊断技术的知识，这些合作加快了伴随诊断的开发，简化了监管审批流程，并提高了个人化医疗选择的可及性。随着精准医疗需求的不断增长，这些合作对于透过开发全面的端到端解决方案来拓宽市场供应至关重要，这些解决方案有助于促进标靶治疗的开发。例如，2024年，BD（碧迪公司）和Quest Diagnostics宣布建立全球合作伙伴关係，共同开发基于流式细胞仪的癌症和其他疾病的伴随诊断。该合作旨在为製药业提供端到端解决方案，涵盖从探索性检测组开发到FDA批准的诊断试剂盒的各个环节。其目标是推进个人化医疗并改善临床疗效。

加强诊断审批的监理途径

诊断审批监管流程的进步和改进是推动市场成长的关键因素。监管机构正在简化伴随诊断的审批流程，以认可其对精准医疗发展的重要贡献。随着审查週期的缩短以及伴随诊断测试创建和授权的明确框架，监管环境对该领域的创新的支持日益增强。这些改进不仅促进了新型诊断技术的进步，也为投资伴随诊断的公司提供了更明确的市场准入途径。此外，随着监管机构认识到这些评估在确保新型疗法疗效方面的重要性，它们也为伴随诊断公司创造了更多发展机会。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球伴随诊断市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品与服务

  • 检测试剂盒和试剂
  • 软体和服务

第七章：市场区隔：依技术

  • 免疫组织化学（IHC）
  • 聚合酶炼式反应（PCR）
  • 原位杂交（ISH）
  • 实时PCR（RT-PCR）
  • 基因定序
  • 其他的

第八章：市场区隔：依指标

  • 癌症
    • 主要类型
      • 肺癌
      • 乳癌
      • 大肠直肠癌
      • 胃癌
      • 黑色素瘤
      • 其他的
  • 神经系统疾病
  • 传染病
  • 心血管疾病
  • 其他的

第九章：市场区隔：依最终用户

  • 製药和生物製药公司
  • 参考实验室
  • 合约研究组织
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Agilent Technologies
    • BioMerieux
    • Danaher Corporation
    • Roche Holding AG
    • Myriad Genetics Inc.
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc.
Product Code: SR112025A2548

The global companion diagnostics market size reached USD 7.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.11% during 2025-2033. North America leads the market attributed to its advanced healthcare infrastructure, high adoption of personalized medicine, and strong regulatory support. The region also benefits from significant investments in research operations and a growing number of biotechnology and pharmaceutical companies. The rising incidences of cancer, the increasing demand for personalized medicine, and continuous technological advancements, including next-generation sequencing (NGS), are some of the primary factors driving the market growth.

Personalized medicine, which customizes therapies according to a person's genetic profile, is a critical factor propelling the companion diagnostics market demand. Matching particular treatments to a patient's distinct genetic profile necessitates accurate diagnostic tools, resulting in a greater need for companion diagnostics that assist in directing therapeutic choices for improved results and reduced side effects. Apart from this, improvements in diagnostic technologies, particularly in molecular diagnostics and next-generation sequencing (NGS), are notably enhancing the precision and dependability of companion diagnostics. These advancements enable the detection of genetic mutations and biomarkers with improved accuracy, thus increasing the effectiveness of therapies and driving the need for companion diagnostics in medical environments. Furthermore, healthcare investments are increasingly focused on precision medicine, which involves using diagnostic tests to tailor treatments. As more healthcare systems adopt targeted therapies and personalized treatment regimens, there is a higher demand for companion diagnostics, particularly in oncology, where tailored therapies are crucial.

Global Companion Diagnostics Market Trends:

Advancements in Gene Therapy and Rare Disease Diagnostics

With the growing use of gene therapies for genetic disorders, there is an increase in the demand for diagnostic tools that guarantee the safe and efficient use of these therapies. Companion diagnostics play a crucial role in determining which patients qualify for gene therapy, especially in rare genetic disorders where treatment effectiveness significantly relies on specific biomarkers. These diagnostics assist in identifying existing antibodies or genetic elements that may influence therapy effectiveness, guaranteeing that patients get the most suitable treatment. This critical role is actively being addressed by key players in the diagnostic and pharmaceutical industries, who are developing and gaining regulatory approvals for advanced companion diagnostic assays to facilitate the safe and effective administration of gene therapies. In 2024, Labcorp received FDA approval for its nAbCyte(TM) Anti-AAVRh74var HB-FE Assay, a companion diagnostic for Pfizer's gene therapy BEQVEZ(TM) (fidanacogene elaparvovec-dzkt) to treat hemophilia B. The test identified preexisting anti-AAVRh74var antibodies in patients, ensuring safe and effective gene therapy treatment. This approval marked a breakthrough in gene therapy diagnostics for rare genetic disorders.

Integration of AI in Diagnostics

Tools powered by AI improve the speed, accuracy, and efficiency of diagnostic tests by examining extensive datasets, such as genetic and clinical data, to pinpoint biomarkers with unmatched precision. AI algorithms can aid in forecasting patient reactions to particular therapies, allowing for more tailored treatment strategies. In oncology and various complex conditions, AI enhances the process of selecting patients for clinical trials, guaranteeing that only those with the highest potential to benefit from the treatment are included. This technological progress is further solidified by strategic collaborations between companies, integrating AI-powered solutions to refine diagnostic processes and accelerate clinical trial advancements. In 2024, ABION and Deep Bio signed an MOU in Seoul, South Korea to collaborate on AI-driven companion diagnostics and cancer clinical trials. The partnership integrated Deep Bio's AI-powered pathology tools into ABION's drug pipeline to enhance precision in patient selection and accelerate trial efficiency. This supported ABION's ongoing combination trials in lung cancer therapy.

Increased Healthcare Investments

Investments in healthcare is a key factor influencing the market as worldwide healthcare systems aim to enhance treatment results and lower expenses. Governments, private investors, and healthcare organizations are focusing on personalized and precision medicine, which directly entails the utilization of companion diagnostics. By pinpointing the most effective therapies, companion diagnostics can minimize the trial-and-error method frequently encountered in traditional treatments, resulting in a more efficient allocation of healthcare resources. Moreover, the growing focus on value-based healthcare, linking reimbursement to patient results instead of care volume, corresponds effectively with the function of companion diagnostics in enhancing treatment precision. The cost-efficiency of targeted treatments facilitated by companion diagnostics further reinforces their incorporation into global healthcare systems. With rising economic pressures on healthcare systems, investments in tools that enhance efficient and effective care, like companion diagnostics, are strengthening the market growth.

Global Companion Diagnostics Market Growth Drivers:

Rising Aging Population

With the growing geriatric population, there is a rise in the prevalence of chronic and age-related illnesses, such as cancer, heart diseases, and neurological conditions. Older adults frequently need more tailored therapies, which can yield the best outcomes when customized to their genetic profile. The World Health Organization (WHO) states that by 2030, one out of every six individuals worldwide will be 60 years or older, and this figure is expected to climb to 2.1 billion by 2050. This demographic change necessitates increased and enhanced diagnostic services, driving the demand for superior diagnostic instruments and testing solutions. Companion diagnostics allow healthcare professionals to customize treatments according to specific genetic profiles, enhancing treatment results and lowering the likelihood of negative reactions. This movement towards individualized healthcare is crucial for addressing the intricate requirements of aging populations.

Strategic Partnerships and Collaborations

Partnerships and collaborations between diagnostic companies and pharmaceutical firms facilitate the combination of diagnostic tools with innovative therapies, guaranteeing that suitable patients obtain the most efficient treatments. Through the integration of knowledge in drug development and diagnostic technologies, these collaborations expedite the creation of companion diagnostics, simplify the regulatory approval process, and improve the accessibility of personalized healthcare options. With the increase in demand for precision medicine, these collaborations are vital for broadening the market offerings by developing all-encompassing, end-to-end solutions that facilitate the creation of targeted treatments. For example, in 2024, BD (Becton, Dickinson and Company) and Quest Diagnostics announced a global partnership to created flow cytometry-based companion diagnostics for cancer and other diseases. The partnership aimed to offer an end-to-end solution for the pharmaceutical industry, ranging from exploratory panel development to FDA-approved diagnostic kits. The goal was to advance personalized healthcare and improve clinical outcomes.

Enhancing Regulatory Pathways for Diagnostic Approval

The advancement and improvement of regulatory processes for diagnostic approval are a crucial factor impelling the market growth. Regulatory agencies are simplifying the approval pathways for companion diagnostics, acknowledging their vital contribution to facilitating precision medicine. With quicker review periods and explicit frameworks for the creation and authorization of companion diagnostics tests, the regulatory landscape is becoming increasingly supportive of innovation in this area. These enhancements not only promote the advancement of novel diagnostic technologies but also offer more defined routes to market access for firms investing in companion diagnostics. In addition, as regulators recognize the significance of these assessments in guaranteeing the efficacy of novel treatments, they are generating more chances for companion diagnostics companies to prosper.

Companion Diagnostics Industry Segmentation:

Breakup by Product & Service:

  • Assays, Kits and Reagents
  • Software and Services

Assays, kits and reagents hold the largest market share

Assays, kits, and reagents play important roles in identifying patients who are most likely to benefit from a particular therapeutic product. These diagnostic tools aid in determining the absence or presence of specific biomarkers, protein expressions, genetic mutations, etc., linked to the potential side effects and effectiveness of targeted therapies. This, in turn, is propelling the market growth in this segment.

Breakup by Technology:

  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • In-situ Hybridization (ISH)
  • Real-time PCR (RT-PCR)
  • Gene Sequencing
  • Others

Polymerase chain reaction (PCR) exhibits a clear dominance in the market

The growth in this segmentation is bolstered by the easy availability of polymerase chain reaction (PCR) kits and reagents used for companion diagnostics. Moreover, their widespread applications in detecting gene mutations with low or limited allele frequencies are contributing to their dominance in the global market.

Breakup by Indication:

  • Cancer
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Melanoma
    • Others
  • Neurological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others

Cancer currently accounts for the majority of the total market share

The widespread incidence of cancer is propelling the usage of companion diagnostics, thereby fueling the market growth in this segmentation. According to the American Cancer Society, in January 2022, 1.9 million cancer cases were recorded in the U.S. Consequently, continuous product launches and approvals by government bodies are positively influencing the companion diagnostics market growth in this segmentation. For example, in October 2021, the United States Food and Drug Administration approved Agilent's Ki-67 IHC MIB-1 pharmDx (Dako Omnis), which assisted in identifying patients with early breast cancer (EBC). Besides this, according to the Lung Cancer Research Foundation, in the United States estimated 236,740 individuals were diagnosed with lung cancer in 2022, thereby propelling the need for lung cancer companion diagnostics.

Breakup by End User:

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations
  • Others

Pharmaceutical & biopharmaceutical companies hold the largest market share

The rising adoption of companion diagnostics by pharmaceutical & biopharmaceutical companies in drug development is one of the primary factors propelling the market growth in this segmentation. Moreover, the inflating popularity of companion diagnostics biomarkers is also acting as another significant growth-inducing factor.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest companion diagnostics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America currently dominates the global market, with the United States emerging as a major contributor. Strategic collaborations among biopharmaceutical companies and companion diagnostic manufacturers are primarily augmenting the regional market. For example, QIAGEN and Denovo Biopharma partnered to develop a companion diagnostic test for the treatment of diffuse large B-Cell Lymphoma (DLBCL). Furthermore, the increasing drug approvals by governing authorities, such as the United States Food and Drug Administration (US FDA), are projected to bolster the companion diagnostics market in North America over the forecasted period.

Leading Key Players in the Companion Diagnostics Industry:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies
  • BioMerieux
  • Danaher Corporation
  • Roche Holding AG
  • Myriad Genetics Inc.
  • Siemens Healthcare
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global companion diagnostics market in 2024?
  • 2.What is the expected growth rate of the global companion diagnostics market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global companion diagnostics market?
  • 4.What are the key factors driving the global companion diagnostics market?
  • 5.What is the breakup of the global companion diagnostics market based on the product & service?
  • 6.What is the breakup of the global companion diagnostics market based on the technology?
  • 7.What is the breakup of the global companion diagnostics market based on the indication?
  • 8.What is the breakup of the global companion diagnostics market based on the end user?
  • 9.What are the key regions in the global companion diagnostics market?
  • 10.Who are the key players/companies in the global companion diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Companion Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product & Service

  • 6.1 Assays, Kits and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Software and Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Immunohistochemistry (IHC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymerase Chain Reaction (PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 In-situ Hybridization (ISH)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Real-time PCR (RT-PCR)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Gene Sequencing
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Lung Cancer
      • 8.1.2.2 Breast Cancer
      • 8.1.2.3 Colorectal Cancer
      • 8.1.2.4 Gastric Cancer
      • 8.1.2.5 Melanoma
      • 8.1.2.6 Others
    • 8.1.3 Market Forecast
  • 8.2 Neurological Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cardiovascular Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical & Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Reference Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Contract Research Organizations
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 BioMerieux
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Roche Holding AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 Myriad Genetics Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Siemens Healthcare
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Thermo Fisher Scientific Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Companion Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Companion Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Companion Diagnostics Market: Breakup by Product & Service (in %), 2024
  • Figure 4: Global: Companion Diagnostics Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Companion Diagnostics Market: Breakup by Indication (in %), 2024
  • Figure 6: Global: Companion Diagnostics Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Companion Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Companion Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Companion Diagnostics (Assays, Kits and Reagents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Companion Diagnostics (Assays, Kits and Reagents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Companion Diagnostics (Software and Services) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Companion Diagnostics (Software and Services) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Companion Diagnostics (Immunohistochemistry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Companion Diagnostics (Immunohistochemistry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Companion Diagnostics (Polymerase Chain Reaction) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Companion Diagnostics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Companion Diagnostics (In-situ Hybridization) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Companion Diagnostics (In-situ Hybridization) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Companion Diagnostics (Real-time PCR) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Companion Diagnostics (Real-time PCR) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Companion Diagnostics (Gene Sequencing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Companion Diagnostics (Gene Sequencing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Companion Diagnostics (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Companion Diagnostics (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Companion Diagnostics (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Companion Diagnostics (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Companion Diagnostics (Neurological Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Companion Diagnostics (Neurological Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Companion Diagnostics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Companion Diagnostics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Companion Diagnostics (Cardiovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Companion Diagnostics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Companion Diagnostics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Companion Diagnostics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Companion Diagnostics (Pharmaceutical & Biopharmaceutical Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Companion Diagnostics (Pharmaceutical & Biopharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Companion Diagnostics (Reference Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Companion Diagnostics (Reference Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Companion Diagnostics (Contract Research Organizations) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Companion Diagnostics (Contract Research Organizations) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Companion Diagnostics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Companion Diagnostics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: North America: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: North America: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United States: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United States: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Canada: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Canada: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Asia Pacific: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Asia Pacific: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: China: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: China: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Japan: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Japan: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: India: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: India: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: South Korea: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: South Korea: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Australia: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Australia: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Indonesia: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Indonesia: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Europe: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Europe: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Germany: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Germany: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: France: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: France: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: United Kingdom: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: United Kingdom: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Italy: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Italy: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Spain: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Spain: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Russia: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Russia: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Latin America: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Latin America: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Brazil: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Brazil: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Mexico: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Mexico: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Others: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Others: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Middle East and Africa: Companion Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Middle East and Africa: Companion Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 91: Middle East and Africa: Companion Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Global: Companion Diagnostics Industry: SWOT Analysis
  • Figure 93: Global: Companion Diagnostics Industry: Value Chain Analysis
  • Figure 94: Global: Companion Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Companion Diagnostics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Companion Diagnostics Market Forecast: Breakup by Product & Service (in Million USD), 2025-2033
  • Table 3: Global: Companion Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: Companion Diagnostics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Companion Diagnostics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Companion Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Companion Diagnostics Market Structure
  • Table 8: Global: Companion Diagnostics Market: Key Players